Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results - ScienceDirect
Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study | SpringerLink
Frontiers | Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus
The Cost-Effectiveness of Initial vs. Delayed Lanreotide for Treatment of Metastatic Enteropancreatic Neuroendocrine Tumors in
PFS in GEP-NETs Patients | Somatuline® Depot 120mg Injection | HCP
Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial – Prodige 31 REMINET: An FFCD study ...
Duilio Rocha Filho on Twitter: "3⃣ REMINET trial - lanreotide vs placebo as maintenance after 1st line Rx (chemo in 96%) in pts w/ aggressive G1-2 duodenopancreatic NETs (N=53) ✔️6-mo PFS 54%
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors | NEJM
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors | NEJM
Essential Concepts in the Use of Somatostatin Analogues in Patients with Neuroendocrine Tumors (Transcript)
Electronic Autoinjector for Somatuline® Autogel® / Somatuline® Depot ( lanreotide)
PFS for lanreotide autogel/depot from the CLARINET core study and the... | Download Scientific Diagram
Carcinoid Syndrome | Somatuline® Depot 120mg Injection | HCP
Impact of Diabetes and Metformin Use on Enteropancreatic Neuroendocrine Tumors: Post Hoc Analysis of the CLARINET Study
Clinical Trial: Phase II CLARINET FORTE Somatuline Autogel (Lanreotide) increased dosing frequency - Ronny Allan - Living with Neuroendocrine Cancer
Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study - UCL Discovery
PFS for lanreotide autogel/depot from the CLARINET core study and the... | Download Scientific Diagram
Reassessing the Role of Somatostatin Analogs in the Treatment of NETs (Transcript)
Treatment of neuroendocrine tumors: new recommendations based on the CLARINET study
Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study | SpringerLink
GTG on Twitter: "Pavel et al, ph 2 CLARINET FORTE trial. High dose lanreotide in progressive GEP-NETs: - mPFS 5.6 mo in PanNET cohort - mPFS 8.3 mo in migut cohort -
Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study in: Endocrine-Related Cancer Volume 23 Issue 3 (2016)
Patient flow diagram. Further details of patient disposition from the... | Download Scientific Diagram
![PDF] Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/a82b998becc9ea2f23aed89d6c17821920c6b73b/4-Figure1-1.png "PDF] Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study | Semantic Scholar")